Description

NSI-189

(freebase, bulk powder)

NSI-189 is a new organic compound developed (and patented in 2009) by Neuralstem company, demonstrating stimulation of neurogenesis and antidepressant-like activity. Neuralstem is a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology. NSI-189 stimulates neurogenesis improving cognitive impairments reversing brain degeneration in the human hippocampus. The hippocampus area of the brain is in charge of spatial control and consolidation of short-term memory to long-term memory. This suggests that NSI-189 could be used as a nootropic to improve cognition. This neurogenesis-promoting drug and is undergoing clinical trials in the treament of Alzheimer’s, stroke, cerebral trauma, major depressive disorder (MDD) and other neurodegenerative diseases.

Mechanism of action: NSI-189 demonstrated the upregulation of growth factors (stem cell factor, brain-derived neurotrophic factor, vascular endothelial growth factor and glial cell-derived neurotrophic factor) to increase neurite outgrowth.

NSI-189 dosage 40mg

CAS 1270138-40-3

Formula C₂₂H₃₀N₄O

Mass 366.5 Da

Synonyms (4-benzylpiperazin-1-yl)(2-(isopentylamino)pyridin-3-yl)methanone

References:

1. The Neurogenic Compound, NSI-189 Phosphate: A Novel Multi-Domain Treatment Capable of Pro-Cognitive and Antidepressant Effects

2. Remediation of Radiation-Induced Cognitive Dysfunction Through Oral Administration of the Neuroprotective Compound NSI-189

3. Enhancement of Synaptic Plasticity and Reversal of Impairments in Motor and Cognitive Functions in a Mouse Model of Angelman Syndrome by a Small Neurogenic Molecule, NSI-189

4. A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189 Phosphate, a Neurogenic Compound, Among Outpatients With Major Depressive Disorder